Navigation Links
AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Date:2/12/2008

QUEBEC CITY, Feb. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that dosing of AEZS-108, a luteinizing hormone-releasing hormone (LHRH) agonist linked to doxorubicin, has commenced in its Phase 2 trial in gynaecological cancers for which patient enrolment had begun in December 2007. This open-label, non-comparative multi-center Phase 2 trial will treat up to 82 women with LHRH-receptor positive ovarian and endometrial cancerous tumors. The primary endpoint for the trial will be the partial or complete tumor response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) and/or Gynaecologic Cancer Intergroup (GCIG) guidelines. The trial is being conducted in 15 centers in Europe under the supervision of lead investigator, Prof. Gunter Emons, M.D., of the Georg-August-University, Gottingen Institute of Gynaecology and Obstetrics in Gottingen, Germany.

David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented, "We are excited to have started dosing patients in our Phase 2 trial with AEZS-108, our highest priority oncology compound. We believe that our approach targeting only patients with LHRH-receptor expressing tumors using doxorubicin is key to both potential increased individual patient safety and potential augmented clinical benefit, while ultimately providing us results that will be pivotal in formulating the next steps in the clinical development of this novel agent."

About the Phase 2 trial

Entitled, "The antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin in women with LHRH-receptor positive gynaecological tumors", this Europe
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
2. AEterna Zentaris Announces Outcome of Managements Strategic Review
3. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Immtech Reports Fiscal Third Quarter 2008 Results
7. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
10. Bunge Reports Fourth Quarter Net Income of $245 Million
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013 Kitware , ... today announces new Phase II SBIR funding from ... development of an open-source, high performance computing (HPC) ... framework enables researchers to select only the toolkits ... simulation, computation, or analysis tasks. , Manufacturers ...
(Date:5/16/2013)... May 16, 2013 Scientists at the Center ... , and the California -based ... a novel therapy for reversing memory decline in mice ... find significant cognitive improvement in advanced stage AD mice. ... for reversing cognitive decline for advanced stage AD mice, ...
(Date:5/16/2013)... NEW YORK , May 16, ... a new market research report is ...   Competitor Analysis: ... Biosuperiors http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ...   The ...
(Date:5/16/2013)... DNA Genotek, a leading provider of products for biological ... in conjunction with the African Society of Human Genetics (AfSHG). ... the cost of DNA collection for locally and ... Health in Africa (H3 Africa) Initiative and to facilitate growth ... AfSHG is to build the capacity of African ...
Breaking Biology Technology:Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3
... Insmed Inc. (Nasdaq:,INSM), a developer of follow-on ... a hearing before a Nasdaq Listing,Qualifications Panel to ... common stock from the Nasdaq Global Market., ... Market ("Nasdaq") on,December 20, 2007 indicating that the ...
... Resigns as President and CEO -, DALLAS, Dec. ... today that current Chairman Jeffrey B.,Davis has been appointed ... resigned as President and CEO of the Company for ... of Directors., "I believe that Access has an ...
... Dec. 26 The Ensign,Group, Inc. (Nasdaq: ENSG ... nursing, rehabilitative care services and assisted living,companies, today announced ... dividend of $0.04 per share of Ensign common stock, ... record as of December 31,2007. Ensign paid annual cash ...
Cached Biology Technology:Insmed to Appeal Delisting Notification From Nasdaq 2Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO 2Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO 3
(Date:5/16/2013)... May 16, 2013 The relationship between the ... has not been clear. Schizophrenia is commonly associated ... There are clues that reduced IQ may be ... example, reduced cognitive ability may precede the onset ... present in healthy relatives of people diagnosed with ...
(Date:5/16/2013)... Integrated Biometrics patented LES (Light Emitting ... film transistor camera introduces Sherlock, a fingerprint scanner ... the smallest and lightest form factor available on ... ID FAP 45, Certified scanner is highly efficient ... weight when compared to optical scanners. ...
(Date:5/16/2013)... million years old give unprecedented insight into the ... the most species-rich groups among the modern bony ... Reichenbacher from the Division of Paleontology and Geobiology ... at Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany have ... they assign to the group of bony fishes ...
Breaking Biology News(10 mins):Genetic risk for schizophrenia is connected to reduced IQ 2Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... Stanford University researchers demonstrated for the first time ... (PET)/computed tomography (CT) images for "fly-through" and "fly-around ... according to a study in the July issue ... powerful ability to meld functional data with accurate ...
... people while they walk, researchers have improved our understanding of ... the same time, the researchers found that the stimulus could ... was walking straight ahead to be steered by "remote control" ... Richard Fitzpatrick and Jane E. Butler of the Prince of ...
... University of Cincinnati (UC) researchers say exposure to a ... we breathe every day--can make young children more susceptible ... The team found that infants who were exposed to ... in life were more likely to develop allergies to ...
Cached Biology News:Coming soon: 3-D imaging that flies 'through' and 'around' cancer 2Coming soon: 3-D imaging that flies 'through' and 'around' cancer 3Stimulation of the semicircular canals can artificially control human walking and balance 2Airborne mold spores increase kids' risk for multiple allergies 2
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Polyethylene Glycol 8000, 1 kg. PEG 8000.Used in differential DNA precipitation. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
See product name for description....
Biology Products: